The medical technology company Pexa was presented by CEO Tomas Gustafsson at at Life Science-dagen in Göteborg on Wednesday.Pexa offers a patented, non-invasive technology to collect biomarkers from the lungs’ small airways via exhaled air. There are currently around 30 instruments in use globally. Pexa is now working on three focus areas to build value. These are mapping of the small airways, drug studies, and diagnostics. - We want to be a tool for the early detection of lung cancer, says Tomas Gustafsson, emphasizing that early detection is crucial for survival from the disease. For the full year 2025, Pexa reported revenue of SEK 0.5 million with an operating loss of SEK 6.3 million. Cash and bank were SEK 6.2 million at year-end. The year-end report states that the board assesses that liquid funds are not sufficient to finance the next twelve months of operations and planned aggressive initiatives. The board is in discussions on how the company will be provided with additional capital.